- Trials with a EudraCT protocol (153)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
153 result(s) found for: Hyperplasia.
Displaying page 1 of 8.
EudraCT Number: 2007-002598-30 | Sponsor Protocol Number: AEZS-102-036 | Start Date*: 2008-02-08 | |||||||||||
Sponsor Name:Aeterna Zentaris GmbH | |||||||||||||
Full Title: Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (PBH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004811-53 | Sponsor Protocol Number: PMX GE IT 304 | Start Date*: 2005-04-28 | |||||||||||
Sponsor Name:PIERRE FABRE PHARMA | |||||||||||||
Full Title: Ex-vivo study regarding the effects of Serenoa r. on the expression of VEGF vascular endothelial growth factor and microvessel density in patients with benign prostatic hypertrophy | |||||||||||||
Medical condition: benign prostatic hypertrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004865-17 | Sponsor Protocol Number: AEZS-102-041 | Start Date*: 2008-08-15 | |||||||||||
Sponsor Name:Aeterna Zentaris GmbH | |||||||||||||
Full Title: Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004381-19 | Sponsor Protocol Number: NBI-74788-CAH2006 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) DE (Completed) FR (Ongoing) PL (Ongoing) BE (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002796-32 | Sponsor Protocol Number: BAY 38-9456 / 11863 | Start Date*: 2005-10-17 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia | |||||||||||||
Medical condition: Benigne Prostatic Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003414-34 | Sponsor Protocol Number: D-20762-Z033 | Start Date*: 2007-11-12 | |||||||||||
Sponsor Name:Aeterna Zentaris GmbH | |||||||||||||
Full Title: Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1year placebo-controlled efficacy study and long-term safety assessment | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (PBH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005252-32 | Sponsor Protocol Number: 027SC06018 | Start Date*: 2006-12-14 | |||||||||||
Sponsor Name:ANGELINI | |||||||||||||
Full Title: A PILOT STUDY OF PRULIFLOXACIN VS. LEVOFLOXACIN IN PREVENTION OF POST-OPERATIVE URINARY BACTERIAL INFECTIONS IN PATIENTS UNDERGOING TURP | |||||||||||||
Medical condition: ANTIBIOTIC PROPHYLAXIS FOR TRANSURETHRAL PROSTATIC RESECTION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001212-20 | Sponsor Protocol Number: 905-CL-057 | Start Date*: 2009-07-16 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male ... | |||||||||||||
Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) IT (Completed) DE (Completed) FR (Completed) HU (Completed) SK (Completed) BE (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004878-34 | Sponsor Protocol Number: ATR-101-202 | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004764-22 | Sponsor Protocol Number: SPR001-203 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Spruce Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) IT (Ongoing) LT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000154-76 | Sponsor Protocol Number: BXL628 02 14 | Start Date*: 2005-03-16 | |||||||||||
Sponsor Name:BIOXELL SPA | |||||||||||||
Full Title: A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosi... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005822-23 | Sponsor Protocol Number: REK231814 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Haukeland University Hospital | |||||||||||||
Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002841-21 | Sponsor Protocol Number: H6D-MC-LVHJ(a) | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005793-31 | Sponsor Protocol Number: 304001 | Start Date*: 2008-04-16 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostat... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) GB (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004321-15 | Sponsor Protocol Number: H6D-MC-LVHK(b) | Start Date*: 2007-12-14 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P... | |||||||||||||
Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000915-53 | Sponsor Protocol Number: DEXAPAE | Start Date*: 2020-10-08 | |||||||||||
Sponsor Name:Department of Radiology, Rigshospitalet, Denmark | |||||||||||||
Full Title: Randomized double-blind placebo-controlled trial on the efficiency of a single dose dexamethasone in reducing the postembolization syndrome in men undergoing prostatic artery embolization for benig... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004873-17 | Sponsor Protocol Number: NBI-74788-CAH3003 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) FR (Ongoing) PT (Ongoing) BG (Ongoing) PL (Ongoing) GR (Ongoing) AT (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001073-94 | Sponsor Protocol Number: TH CR-202 | Start Date*: 2005-12-27 |
Sponsor Name:Threshold Pharmaceuticals Inc | ||
Full Title: A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia | ||
Medical condition: Benign Prostatic Hyperplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: HU (Ongoing) IT (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002395-40 | Sponsor Protocol Number: AGO/2013/007 | Start Date*: 2014-03-24 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: Prospective intervention trial with adjuvant metformin in girls and boys with classic CAH (METFOR CAH). | |||||||||||||
Medical condition: congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004765-40 | Sponsor Protocol Number: SPR001-204 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:Spruce Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) IT (Ongoing) EE (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.